OREANDA-NEWS. Protek Group (PRTK: RTS, MICEX), a major Russian pharmaceutical company announces its preliminary operational results for Q4-2014 and 12M-2014 according to the management accounts (unaudited).

In Q4-2014, the consolidated revenue of the Group increased by 21.2% y-o-y to RUB 47,318 mln.

In 12M-2014, the Group's consolidated revenue increased by 12.5% y-o-y to RUB 156,674 mln.

The Group's revenue growth for 12M-2014 was driven by all the business segments, each showing an uptrend.

In 12M-2014, the Distribution Segment made up 80.7% of the Group's total revenue*.

RETAIL Segment

Total of 1202 retail outlets were active as at 31 December 2014.

In Q4-2014, 87 pharmacies were organically opened and 7 pharmacies were closed.

In 12M-2014, 262 pharmacies were organically opened and 52 pharmacies were closed.

In 12M-2014, the Retail Segment made up 14.7 % of the Group's total revenue.

Like-for-Like (L-f-L) Sales:

As at 31 December 2014, there were 732 Like-for-Like pharmacies in the Retail Segment.

Low-price pharmacies:

As at 31 December 2014, low-price pharmacies accounted for 606 pharmacies.

In 12M-2014, low-price pharmacies' revenue increased by 9.2% y-o-y, traffic was down 1.7%.

In 12M-2014, low-price pharmacies made up 43.7 % of the Retail Segment.

In 12M-2014, the proprietary brand revenue surged by 5% to RUB 4,462 mln. against RUB 4,242 mln. in 12M-2013 .

The 12M-2014 revenue boost was due to a sales increase of proprietary products (Chondrogard, Likferr 100, Cereton, Amelotex, CompligamB).

In 12M-2014, the Production Segment made up 4.6 % of the Group's total revenue.

Vadim Muzyaev, President of PROTEK Group: "The fourth quarter of 2014 was successful for Protek Group as well as for other players on the pharmaceutical market; our growth rate of 21.2% exaggerated the market one (13.3% in Q4-2014). Our Distribution segment (as well as Retail segment) showed a positive dynamic due to a strong demand for both pharmaceutical and parapharmaceutical products. We are satisfied with FY-2014 operational results, which consolidated revenue growth rate amounted to 12.5%, that outstripped the 9.3% market growth rate in Rouble terms".